Based on our deep science and focused on patients in need.
AvenCell has raised $6.0M in total funding. The most recent round was Series C. The last funding was announced in September 2026.
AvenCell's investors include Novo Holdings, Blackstone Life Sciences, Ligand Pharmaceuticals, F-Prime, Eight Roads Ventures Japan.
AvenCell is headquartered in Watertown, United States.
Based on our deep science and focused on patients in need.
AvenCell is at the Series C stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"AvenCell — Funding & Investors." VCBacked, September 24, 2026, https://www.vcbacked.co/company/avencell. Accessed October 31, 2026.
VCBacked. (2026). AvenCell — Funding & Investors. Retrieved October 31, 2026, from https://www.vcbacked.co/company/avencell
{{cite web |title=AvenCell — Funding & Investors |url=https://www.vcbacked.co/company/avencell |website=VCBacked |access-date=October 31, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated